EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

Authorised approval for Yervoy (ipilimumab) with multiple indications including melanoma and various carcinomas and mesothelioma; decision date 07/05/2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Non-small-cell Lung
• Carcinoma Renal Cell
• Colorectal Neoplasms
• Melanoma
• Mesothelioma Malignant

Drugs mentioned

• Yervoy (ipilimumab)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 07/05/2026